Skip to content
OpenCapital
Get started

Emergent Biosolutions EBS Enterprise value

Enterprise value at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$222.48B+0.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$81.42B+18.1%
AMP
Amphastar PharmaceuticalsAMPH
$1.4B-24.1%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$6.34B+33.4%
CorMedix logo
CorMedixCRMD
$774.78M+71.7%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$765.76M-9.8%

Other financials

Income statement

See full
Revenue$156.1M-29.7%
Gross profit$84.1M-37.1%
Operating income$10.5M-79.0%
Net income$6.8M-90.0%
EPS (diluted)$0.07-94.1%

Balance sheet

See full
Cash & equivalents$161.5M+5.7%
Total debt$584.6M-13.1%
Total equity$523.1M-5.4%
Total assets$1.3B-7.4%

Cash flow

See full
Operating cash flow-$33.8M-202%
CapEx$2.4M-33.3%
Free cash flow-$36.2M-145%

Valuation

See full
Market cap$411.74M+22.0%
P/E3.6×—
P/S0.6×+0.3×

Profitability

See full
Gross margin54.2%+19.0pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin20.8%—

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.1×-0.1×
Current ratio4.3×-2.0×

Where this comes from

Calculated from Emergent Biosolutions’s reported figures.

$428.6Mmarket cap+$584.6Mtotal debt−$161.5Mcash and equivalents=$851.75M

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Emergent Biosolutions's enterprise value?
Emergent Biosolutions (EBS) reported enterprise value of $851.75M in Q1 2026.
How has Emergent Biosolutions's enterprise value changed year-over-year?
Emergent Biosolutions's enterprise value increased by 8.6% year-over-year, from $783.98M to $851.75M.
What is the long-term trend for Emergent Biosolutions's enterprise value?
Over 5 years (2020 to 2025), Emergent Biosolutions's enterprise value has grown at a -27.5% compound annual growth rate (CAGR), from $5.11B to $1.02B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.